tbuckley/cabot-search huggingface dataset:
Mediastinal Mass with Bone Marrow Involvement Is a Favorable Factor for Childhood T-Lymphoid Malignancy in Japan.
Authors: Megumi Oda, Keiko Yumura-Yagi, Junichi Hara, Shinichiro Nishimura, Akio Tawa, Yoshihiro Komada, Tohru Kudo, Makoto Yoshida, Ryoji Kobayashi, Tetsuya Takimoto, Atsuko Nakagawa, Keizo Horibe
Journal: Blood (2006)
Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy.
Authors: M. G. Holland, A. McCampbell, J. K. Litton, R. L. Theriault, M. M. Ramirez
Journal: Journal of Clinical Oncology (2011)

1106 Background: In women with pregnancy associated breast cancer (PABC), fetal exposure to chemotherapy during the second / third trimester has not been linked to considerable neonatal adverse outcome. Breast cancer resistance protein (BCRP) is a member of the ATP-binding cassette (ABCG2) efflux transporter family localized in the placenta. BCRP has been implicated in preventing passage of chemotherapy across the placenta. Our study examines if exposure to chemotherapy regimens including adriamycin, a known substrate of the transporter, changes placental immunostaining for BCRP. Methods: 13 placentas from women with (PABC) who received 5-fluorouracil, adriamycin and cyclophosphamide (FAC), were collected. Controls matched for gestational age were identified at a 1:1 ratio. Immunohistochemistry was performed using the BXP-21 monoclonal antibody (Santa Cruz Biotechnology, Inc) specific to the BCRP protein. Staining intensity was quantified in 10 chorionic villi per slide using the Image Pro (Version 7.0) software. All measurements were standardized and taken using a grey value scale (gvs) according to the software specifications. Samples were run in triplicate. Investigators were blinded to case/control status. Analysis was performed (STATA statistical software package, version 10.0). Kruskal-Wallis rank test was utilized for comparison between case and control groups. Results: Median density for case samples was 107.13 (IQR 101.1 – 118.7) gvs compared to 78.97 (IQR 77.09 – 87.9) gvs for controls. Kruskal-Wallis rank test was significant ( p = 0.0001), with cases scoring significantly higher than controls. Within the chemotherapy group, there was not a significant difference in density between those cases receiving ≤ 4 cycles of FAC (n=7) and those receiving ≥5 cycles (n = 6), p = 0.78. Conclusions: Administration of FAC during pregnancy appears to increase placental BCRP immunostaining. The observed increase in BCRP may account for diminished transfer of chemotherapy agents to the fetus, therefore limiting exposure. This novel finding could have implications in treating women with PABC.
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
Authors: MoonSun Jung, Amanda J. Russell, Bing Liu, Joshy George, Pei Yan Liu, Tao Liu, Anna DeFazio, David D.L. Bowtell, André Oberthuer, Wendy B. London, Jamie I. Fletcher, Michelle Haber, Murray D. Norris, Michelle J. Henderson
Journal: Cancer Research (2016)

Abstract Myc transcriptional activity is frequently deregulated in human cancers, but a Myc-driven gene signature with prognostic ability across multiple tumor types remains lacking. Here, we selected 18 Myc-regulated genes from published studies of Myc family targets in epithelial ovarian cancer (EOC) and neuroblastoma. A Myc family activity score derived from the 18 genes was correlated to MYC/MYCN/MYCL1 expression in a panel of 35 cancer cell lines. The prognostic ability of this signature was evaluated in neuroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), and EOC microarray gene expression datasets using Kaplan–Meier and multivariate Cox regression analyses and was further validated in 42 primary neuroblastomas using qPCR. Cell lines with high MYC, MYCN, and/or MYCL1 gene expression exhibited elevated expression of the signature genes. Survival analysis showed that the signature was associated with poor outcome independently of well-defined prognostic factors in neuroblastoma, breast cancer, DLBCL, and medulloblastoma. In EOC, the 18-gene Myc activity signature was capable of identifying a group of patients with poor prognosis in a "high-MYCN" molecular subtype but not in the overall cohort. The predictive ability of this signature was reproduced using qPCR analysis of an independent cohort of neuroblastomas, including a subset of tumors without MYCN amplification. These data reveal an 18-gene Myc activity signature that is highly predictive of poor prognosis in diverse Myc-associated malignancies and suggest its potential clinical application in the identification of Myc-driven tumors that might respond to Myc-targeted therapies. Cancer Res; 77(4); 971–81. ©2016 AACR.
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse
Authors: Nirali N Shah, David Loeb, Hahn Khuu, David Stroncek, Mark Raffeld, Cindy Delbrook, Kelly Richards, Kristin Baird, Jason Levine, Susan F. Leitman, Crystal L Mackall, Terry J Fry, Alan S Wayne
Journal: Blood (2011)
Conditional survival probability of patients with resected pancreatic adenocarcinoma.
Authors: Mark Vikas Mishra, Colin Eamon Champ, Timothy Norman Showalter, Scott W. Keith, Pramila R. Anne, Voichita Bar-Ad
Journal: Journal of Clinical Oncology (2012)

284 Background: The purpose of this study is to evaluate conditional survival (CS) probabilities for patients with resected pancreatic adenocarcinoma (PC) amongst patients who have survived ≥1 more year(s) after diagnosis. Methods: Patients with resected PC from 1998-2008 were identified from the Surveillance, Epidemiology and End Results Database. Data on patient, tumor and treatment characteristics were extracted. Overall survival (OS) rates were calculated using the Kaplan-Meier method. A multivariate analysis (MVA) at different time points from survival was performed to determine independent prognostic factors associated with all-cause mortality hazard ratios (HRs) using Cox proportional hazards models. Results: A total of 4,883 patients with resected PC were identified. Fourteen percent of patients had Stage IA/B disease, 23% Stage IIA, 53% Stage IIB, and 2% Stage IIIA, and 6% with unknown stage. The 1-, 3-, and 5-year survival estimates for patients at diagnosis were 67%, 29%, and 21%, respectively. One, 3- and 5-year survival probabilities conditional upon number of years already survived are shown in table 1. Prognostic factors significantly correlated with improved OS at the time of diagnosis on MVA include: earlier stage, younger age, later year of diagnosis, white race, female gender, and residence in a high income district (p &lt; 0.05). After already surviving 3 years following diagnosis, younger age was the only prognostic factor correlated with improved OS (p&lt;0.05). Conclusions: CS estimates provide additional prognostic information that may be used to counsel PC patients on how their prognosis may change over time. Further research utilizing prospectively-collected data is warranted to help determine recommended follow-up intervals and benchmarks for future clinical trials. [Table: see text]
Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.
Authors: David H. Gordon, Gwen Nichols, Ali Ben-Jacob, Hung Lam, Tom Lillie, Carole Miller
Journal: Blood (2006)
The ANALYSIS of Chimerism IN ACTIVATED T Lymphocites CD25+ Improves the CAPACITY of the T Lymphocytes CD3+ Chimerism Dinamic to Predict COMPLICATIONS AFTER Allogenic STEM CELL TRANSPLANTATION.
Authors: Noriega Concepcion Victor, Gayoso Jorge, David Serrano, Rodriguez Macias Gabriela, Pascual Balsalobre, Ismael Buno Borde, Jose L Diez-Martin
Journal: Blood (2009)
Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas.
Authors: K. A. Robertson, D. C. Bowers, F. Yang, T. Vik, C. Ho, J. Croop, L. E. Walsh, C. Hingtgen, K. R. Pradhan, G. Hutchins, J. W. Fletcher, M. Cohen, M. Edwards-Brown, J. B. Travers, M. Yu, G. Nalepa, S. Denne, D. Ingram, W. Clapp
Journal: Journal of Clinical Oncology (2011)

10030 Background: NF1 is a common inherited disorder resulting from mutations in the neurofibromin gene resulting in a variety of tumors. PN occur in 20-40% of NF1 patients and result from loss of heterozygosity of neurofibromin in Schwann cells. PNs are refractory to conventional chemotherapy and often unresectable. Pre-clinical studies and clinical reports have defined the role of the c-KIT receptor, c-ABL, and PDGFR tyrosine kinases in PN growth and response to the tyrosine kinase inhibitor imatinib. Methods: We conducted a phase II pilot study to examine the response of measurable, clinically significant PNs in NF1 patients to imatinib. The primary 6 month endpoint was PN size by MRI cross sectional area: responsive > 5% reduction; progression > 5% increase; stable < 5% change. Secondary endpoints included symptomatic improvement, expression of 15 plasma cytokines, and safety/toxicity of imatinib. Results: 36 pediatric/adult NF1 patients with PNs were enrolled and treated with imatinib; 440 mg/m2/day in children < 19 years old and 800mg/day in adults 19-52 years old. Eleven grade 3/4 toxicities were observed (wt gain, rash, liver functions and blood counts). 12 patients withdrew from study prior to the 6 month endpoint with 3 from toxicity. Of 24 evaluable patients, 9 (38%) responded with tumor reduction; 2 (8%) with stable disease, and 13 (54%) had progression of tumor growth. Out of 87 PNs measured, 17 had a reduction in size (Table) projecting a relative response rate of 20% for tumor reduction (12-29%, 95% CI). There were 23 PN’s (26%) that progressed and 47 PNs (54%) were stable. Symptom improvement was reported by 6 of 11 (55%) of patients with non-progressive disease and 1 of 13 (8%) of patients with progression (p = 0.023). A panel of 15 plasma cytokines after 6 months of therapy showed > 2 fold increase in levels in 24% of cytokines measured in patients with progressive disease compared to 2% in patients without progression (p< 0.0001). Conclusions: 1) A subset of NF1 patients with PNs treated with imatinib have reductions in tumor size associated with symptom improvement. 2) cytokine expression correlates with tumor response. Max PN reduction after imatinib. % Reduction # PNs 5-10 5 10-20 2 20-25 7 35-45 3
Vigorous Priming of Minor Histocompatibility Antigen Specific T Cells by Frequent High Dose Peptide Vaccination May Lead to Prolonged T Cell Receptor Downregulation, Impaired T Cell Functionality, and Promotion of Tumor Escape.
Authors: Inge Jedema, Linda van Dreunen, Marleen M. van Loenen, Mirjam Heemskerk, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2007)
Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.
Authors: Kenneth R. Carson, Stephen A. Klinge, Steven M. Belknap, June M. McKoy, Dennis W. Raisch, Martin S. Tallman, Timothy M. Kuzel, Andrew M. Evans, Benjamin Kim, Paul R. Yarnold, Elizabeth A. Lyons, Charles L. Bennett
Journal: Blood (2004)
Stored blood: how old is too old?
Authors: Janet S. Lee, Daniel B. Kim-Shapiro
Journal: Journal of Clinical Investigation (2016)

Transfusion of rbc is a routine, often lifesaving procedure that depends on a stored supply of blood. In the US, 42 days is the maximum duration allowed for rbc storage; however, several lines of evidence indicate that patients that receive blood at the upper end of this storage limit are at a higher risk of morbidity and mortality. In this issue of the JCI, Rapido and colleagues evaluated the effects of transfusing one unit of blood close to the storage limit into healthy adults. Compared to those that received rbc stored for five weeks or less, those that received blood stored for six weeks showed several effects associated with increased harm, including disruption in iron handling, increased extravascular hemolysis, and the formation of circulating non–transferrin-bound iron. Together, the results of this study suggest that current maximum storage durations should be carefully reevaluated.
Reticulated Platelets Quantification In An Automatic CBC Counter and Its Role In Thrombocytopenia Etiology Assessment
Authors: Ana Teresa Simoes, Rogério Barreira, Ana Cristina Oliveira, Ana Cristina Pinheiro, Patrícia Ferreira, Marta Duarte, Ramón Salvado, Maria Leticia Ribeiro, Susana Almeida Santos
Journal: Blood (2010)
Multilumen breast brachytherapy in patients with 5 mm or less balloon surface-skin distance using the Contura brachytherapy catheter.
Authors: D. R. Reed
Journal: Journal of Clinical Oncology (2011)

108 Background: To evaluate the toxicity of multilumen breast brachytherapy in patients with 5 mm or less balloon surface-skin distance (BSD) treated with the Contura catheter. Methods: From September 2008 through February 2010 a total of 411 patients with early-stage breast cancer (stages 0, I, IIA) were treated with multilumen HDR brachytherapy for definitive APBI using the Contura brachytherapy catheter. Of those patients 92 had a balloon surface-skin distance (BSD) of 5 mm or less, with 6 months clinical follow-up. All patients received 34 Gy in 10 fractions bid over 5 days. The PTV_EVAL (cc) defined as a 1 cm expansion from the anterior surface of the device; BSD (mm) defined as the distance from the closest point on the balloon to the closet point on the skin surface; maximum skin dose (% and cGy); the volume of breast tissue (cc) receiving 150% and 200% of the prescription dose (V150, V200). Patient toxicity was evaluated at 1 week, 1 month, and 6 months following brachytherapy including; skin reaction (RTOG Acute Radiation Morbidity Scoring Criteria), pigmentation, telangiectasia, pain, fat necrosis, symptomatic seroma. Results: The mean BSD was 3.7 mm, with a range of 1-5 mm. The mean maximum skin dose was 4508 cGy (132.5%). The mean V150 was 21 cc and the V200 was 4.7 cc. The mean PTV_EVAL V90 was 93.7%. 49% of patients had skin reaction, including at 1 week; 47% Grade 1, 0% Grade 2 or 3. At 1 month; 31% Grade 1, 14% Grade 2 and 0% Grade 3. At 6 months; 2% Grade 1, 2% Grade 2 and 0% Grade 3. 6.5 % developed pigmentation changes (hypo or hyper). 5.4% developed telangiectasias, 9.7% reported pain. No patients had fat necrosis, and 15.2 % had a symptomatic seroma. 1 patient had wound dehiscence (maxium skin dose 4195 cGy, 123.4% of prescribed dose). Patients that experienced toxicity had no difference in BSD (3.6 vs 3.9 mm) or in the maximum skin dose (132.6% vs. 132.6%) compared to those that did not experience toxicity. Conclusions: Breast brachytherapy in patients with 5 mm or less BSD has acceptable toxicity with proper planning using the Contura multilumen catheter. Careful attention to maximum skin dose must be used, and we recommend not exceeding 145 % (4,930 cGy) of the prescribed dose.
Preoperative radiotherapy in patients with locally advanced breast cancer: Tumor response and patient outcome after 26 years of median follow-up.
Authors: M. Santos, S. Heymann, F. Fayard, A. Dunant, R. Arriagada, H. Marsiglia, C. Bourgier
Journal: Journal of Clinical Oncology (2011)

113 Background: Preoperative radiotherapy (PreopRT) in locally advanced breast cancer patients (LABC) has been rarely reported. The purpose of this study was to determine if pathological response to PreopRT could have prognostic value on locoregional control and survival. Methods: From 1970 to 1984, 203 LABC patients were treated by PreopRT, delivering 45Gy in 25 fractions to the breast, supraclavicular fossa, axilla and ipsilateral internal mammary chain. After a median interval of 38 days (range: 5-121 days), radical mastectomy and axillary dissection was performed independently of radiation response. Chemotherapy or endocrine therapy was prescribed according to physician discretion in 28% and 11% of patients, respectively. Premenopausal patients underwent ovarian ablation. Median follow-up was 26 years. Locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method, the comparison of survival between groups was performed using the log-rank test, multivariate analysis was performed using the Cox model. Results: Thirty-three patients (16.2%) had a pathologic complete response (pCR) in the breast. The 10- and 20-year Kaplan-Meier LC were 90% (95% confidence interval CI: 85-94%) and 84% (95% CI: 77-89%), respectively. The 10 and 20-years DFS were 49% (CI: 42-55%) and 35% (CI: 29-42%), and the 10 and 20-years OS, 56% (CI: 49-63%) and 41% (CI: 35-48%), in that order. Patients with pCR tended to have better DFS (p=0.06) and OS (p=0.07) when compared to patients with partial response or stable/progressive disease. Having a pCR did not significantly influenced LRC (p=0.44). Multivariate analysis showed that a lower number of positive nodes on axillary dissection and younger age were associated with better DFS (p&lt;0.0001 and p=0.02) and OS (p&lt;0.0001 and p=0.007). Conclusions: LCR achieved by PreopRT followed by radical mastectomy in LABC was excellent in this study, despite few patients having adjuvant systemic therapy. Complete pathologic response defined a subgroup of women with a trend toward better DFS and OS. Older patients and those with a higher number of involved axillary nodes had a worse prognosis.
Chemoradiotherapy plus surgery versus surgery alone for resectable esophageal cancer: A systematic review of randomized control trials.
Authors: Basile M. Njei, Juliet Appiah, Ivo C. Ditah, John W. Birk
Journal: Journal of Clinical Oncology (2012)

94 Background: Several trials have demonstrated better survival when surgery is combined with neoadjuvant chemotherapy and concurrent radiotherapy (CRT) in the treatment of esophageal cancer (EC). However, it is unclear whether survival benefits are counterbalanced by a poor quality of life due to the adverse effects of the combination therapy. The aim of this study was to compare the efficacy and safety of CRT plus surgery versus surgery alone. Methods: Two authors independently conducted a comprehensive search of the Cochrane library PUBMED, MEDLINE, and published proceedings from major oncologic cancer meetings from January 1980 to July 2011. The titles and abstracts of all potentially relevant studies were screened for eligibility. In addition to overall outcome measures, subgroup analysis by histology of EC (squamous cell cancer [SCC] and adenocarcinoma [AC]), was also performed. Analysis was done using the fixed effect model. The Begg’s and Egger’s tests with visual inspection of the funnel plot were used to assess for population bias. Results: Fifteen studies involving 1,957 patients were included in the analysis. There was an overall statistically significant increase in the 5-year survival for the CRT plus surgery group versus the surgery only group (RR 1.47, 95% CI 1.24-1.76). By histological type, only patients with SCC showed prolonged survival: RR 1.53, 95% CI 1.26-1.85. We equally found an overall significant increase in grade 3 and 4 adverse events in the CRT plus surgery group compared to the group with surgery alone (RR 1.73, 95% CI 1.15-2.60). Again, a significant increase in serious adverse events was observed only in the sub-group of patients with SCC (RR 1.81, 95% CI 1.14-2.86). There was no evidence of heterogeneity or publication bias in these analyses. Conclusions: Overall, CRT plus surgery can improve long-term survival in EC patients. The results seem to be limited only to patients with SCC and not AC. However, the prolonged survival comes at the cost of poorer quality of life due to a higher incidence of adverse events. For the moment we recommend that the decision on what treatment strategy to use be based on informed patient preference.
Frequency of a Highly Polymorphic Variant, S36N GFI1, Is Increased in CML Patients
Authors: Jaspal S Kaeda, Leila Amini, Concetta Quintarelli, Iris von Wunsch-Rolshoven, Frauke Ringel, Michaela Schwarz, Fabrizio Pane, Bernd Dörken, Philipp le Coutre
Journal: Blood (2014)
B-Cell Scaffold Protein with Ankyrin Repeats (BANK1) Is Differentially Expressed in ZAP-70 Negative Compared to ZAP-70 Positive Chronic Lymphocytic Leukemia Cells.
Authors: Frank Dicker, Susanne Schnittger, Claudia Schoch, Alexander Kohlmann, Wei-Min Liu, Wolfgang Kern, Torsten Haferlach Prof
Journal: Blood (2005)
Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression
Authors: Jeffrey R Gardner, Michelle Nahas, Jie He, Shlomzion Aumann, Mithat Gonen, Minal Patel, Kristina M. Knapp, Maria Lia Palomba, Roman Yelensky, Amy L Donahue, Geoff Otto, Maria Arcila, Nicole Lamanna, Mark G. Frattini, Ahmet Dogan, Jae H Park, Doron Lipson, Martin S. Tallman, Ross L. Levine, Philip J. Stephens, Marcel R. M. van den Brink, Mark L Heaney, Vincent A. Miller, Andrew D. Zelenetz, Omar Abdel-Wahab
Journal: Blood (2014)
CFU-GEMM Infused Influences Immunologic Recovery in Children Older Than 7 years After Hematopoietic Stem Cell Transplantation.
Authors: Katarzyna Drabko, Marta Choma, Agnieszka Zaucha-Prazmo, Beata Wojcik, Dorota Winnicka, Jerzy Kowalczyk
Journal: Blood (2009)
Frequency and prognostic significance of the PSA flare-up phenomenon in men with castration-resistant prostate cancer (CRPC) who undergo docetaxel-based chemotherapy.
Authors: Charlotte Piper, Thomas van Erps, David J. K. P. Pfister, Robin Epplen, Daniel Porres, Axel Heidenreich
Journal: Journal of Clinical Oncology (2012)

92 Background: Chemotherapy with docetaxel and prednisone represents the guideline-recommended first-line therapy in men with metastatic CRPC. Until now there is a lack of information with regard to the oncological efficacy, survival and treatment-associated toxicity in patients who are treated in the community beside clinical trials. Methods: 487 patients were prospectively recruited according to a standardized questionnaire within a 1-year time interval. Patients were treated in 144 institutions who contributed between 2 and 48 patients. The mean age was 73.4 (41 – 85) years, the mean PSA level was 135.9 (2.1 – 1.895) ng/ml. 445 (91.5%) patients had bone metastases and/or lymph node metastases. Cardiovascular, pulmonary, neurological or endocrinological comorbidities were present in 157 (27.5%) patients. Results: The mean follow-up was 24 (15-36) months. A mean of 6.6 (1-21) cycles docetaxel were delivered. 101 (20.7%) patients received 1-3 cycles, 222 (45.6%) patients received 4-6 cycles and 167 (34.3%) patients underwent 7-10 cycles. 29 (5.9%) and 295 (61.4%) patients achieved a complete or partial remission, respectively; 95 (19.5%) and 19 (3.9%) patients demonstrated stable disease or progression, respectively. An immediate, delayed (flare-up) or no PSA response was achieved in 40.9%, 29.9% and. 21.8%, respectively. During follow-up 192 (40.6%) patients developed progressive disease. 49 (10.4%) patients died, 37 (7.8%) died due to cancer progression. The mean and median progression-free survival was 256.6 ± 14.8 and 216 days, respectively. The mean and median overall survival was 394 ± 10.7 and 476 days, respectively. Significant Grad 3/4 toxicities were identified in 46 (9.4%) patients with predominantly hematotoxicity and gastrointestinal toxicity. Conclusions: We were able to reproduce the therapeutic response rate of clinical studies with a selected pool of patients. We verified the efficacy of docetaxel in general in patients with CRPC. A flare-up phenomenon within the first three cycles was observed in 30% of patients, which suggest to continue therapy for at least that period of time.
Focal Adhesion Kinase Inactivation Reduces the Development of Acute Leukemia and Partially Rescues Hematopoietic Stem Cell Defects in Pten-Knockout Mice
Authors: Dewen You, Andrew Volk, Clare Sun, Junping Xin, Geunhyoung Ha, Chunliu Pan, Rachel Schmidt, Patience Oladeinde, Wei Wei, Subing Zhang, Eun-Kyoung Breuer, Peter Breslin, Jiwang Zhang
Journal: Blood (2012)